One strategist says this under-the-radar tech stock looks attractive now.
Read MoreThe work-from-home trend has sent these 2 stocks soaring, and traders say both are buys for the long-term.
Read MoreWe could be in for a wild ride ahead with the selling amounting to as much as $76 billion.
Read MoreThe market is ignoring these 3 “best in class cyclical businesses,” giving investors a good buying opportunity.
Read MoreWith people staying home as cases of the deadly virus continue to climb, stocks like these 5 are on the rise.
Read MoreTrade Setup Stocks found in this category are low priced stocks priced between .50 and $1, with at least 50k shares of average shares trading per day. The stocks are pausing a trend either up or down, with a new bar over the prior day open or close. These are high reward to risk stocks with the […]
Read MoreTrade Setup Buy Target $36.90 Sell Target $45.42 Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company’s lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men […]
Read MorePlus, bank stocks are on the rise on reports of a change to the Volker Rule, the U.S. saw a record number of new coronavirus cases, last week’s jobless claims came in higher than expected, and Wirecard shares tanked after the troubled fintech filed for insolvency.
Read MoreOver the last several years, one of the biggest benchmarks the Fed has used to evaluate the need to raise, lower or maintain their interest rate policy has been the employment rate. Every month, the market seems to hold its breath as a new set of unemployment and salary data is made available and everybody […]
Read MoreBuy Price: $4.00 or better Sell Price: TradersPro Sell Signal Genprex, Inc. operates as a clinical-stage gene therapy company. The company engages in developing technologies for cancer patients based upon a proprietary technology platform. Its platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then […]
Read More